Announcing a new publication for Acta Materia Medica journal. Proteolysis targeting chimeras (PROTACs), as a novel therapeutic drug model, has received widespread attention from academia and the pharmaceutical industry.
PROTAC technology has led researchers to focus on developing chemical biology tool properties due to the unique operating mechanism and protein dynamic regulatory properties.
In recent years the rapid development of PROTAC technology has gradually made PROTACs an essential tool for target identification and validation. To further promote the application of PROTAC tools in drug discovery and basic medical science research, this article distinguishes target identification and validation concepts. Furthermore, research progress in PROTAC technology is summarized.
https://www.scienceopen.com/hosted-document?doi=10.15212/AMM-2024-0010
